H.C. Wainwright Remains a Hold on Fate Therapeutics (FATE)


In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Fate Therapeutics (NASDAQ: FATE), with a price target of $12. The company’s shares opened today at $11.28.

According to TipRanks.com, White is a 5-star analyst with an average return of 22.9% and a 50.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fate Therapeutics with a $16 average price target.

See today’s analyst top recommended stocks >>

Based on Fate Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $19.65 million. In comparison, last year the company had a GAAP net loss of $9.65 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts